Pharming Group N.V.
PHARNasdaq
$13.47
↑ +1.4%Jul 17 close · end-of-day
Price
1Y↑ +31.4%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
No screener snapshot for this ticker.
Company profile
Pharming Group N.V. develops and commercialize protein replacement therapies and precision medicines. Ruconest, a recombinant human C1 esterase inhibitor, is used for the treatment of acute hereditary angioedema. RhC1INH, leniolisib, a phosphoinositide 3-kinase delta (PI3K delta) to treat patients with activated PI3K Delta syndrome; and alpha-glucosidase therapy for the. treatment of pompe and fabry diseases.
- CEO
- Sijmen d. Vries
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 280
- Website
- pharming.com
Earnings
No reported earnings periods on file.
Financial statements
No annual data.
No quarterly data.
Company news
Jun 15, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
No insider transactions on file.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.